Saturday 17 October 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.
1.21
0.08
−6.20%
Follow PMVP
PMV Pharmaceuticals, Inc. (PMVP) P/E ratio
PMV Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATRA Atara Biotherapeutics, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. | n/m |
| ANIX ANIXA BIOSCIENCES INC compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| MIST Milestone Pharmaceuticals Inc. compare | n/m |
| CBUS Cibus, Inc. compare | n/m |
| NRXS Neuraxis, Inc. compare | n/m |
| ICCC ImmuCell Corporation compare | 126× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)